Respiree, Roche announces AI integration for RPM
Singaporean startup Respiree has tied up with global pharmaceutical and diagnostics company Roche for technology integration.
Respiree will be combining its vital sign monitoring device with Roche's blood glucose device as a joint bedside offering. The solution is also expected to be integrated with machine learning models that predict clinical...
iRhythm Technologies announced it has received another FDA 510(k) clearance for its ZEUS (Zio ECG Utilization Software) System that works with a wearable to monitor patients with atrial fibrillation, an irregular heart rhythm.
Developed in partnership with Alphabet life science subsidiary Verily, the ZEUS System is a platform that works with the Zio Watch to detect AFib, characterize the amount...
Alphabet’s life science branch Verily is teaming up with digital health startup iRhythm on a new initiative focused on creating screening, diagnosis and management tools for patients with atrial fibrillation.
The collaboration is specifically targeted at alerting patients with asymptomatic or silent atrial fibrillation about their condition. The goal is to develop products that not only identify...
According to a new study published this morning in Nature, an algorithm trained via a deep neural network has been able to perform on par with board-certified cardiologists at the annotation of 12 different types of heart rhythms.
Researchers from Stanford University and iRhythm collaborated for the study, which detailed an algorithm trained on 91,232 30-second single-lead ECG readings from 53,...
iRhythm Technologies reported a promising second quarter from a financial standpoint, citing a revenue of $35.5 million, up 55 percent from this time last year. But CEO Kevin King's major focus on the call was not earnings, but a pair of scientific studies published last month in the Journal of the American Medical Association and JAMA Cardiology.
These studies and what they represent could crack...
iRhythm Technologies, maker of the Zio XT and Zio AT adhesive heart monitors, announced first quarter financials boasting higher revenue and an improved gross margin during an earnings call for investors earlier this week. These promising numbers were paired with a net loss nearly double what was reported last year during the same quarter, although these were waved off by executives as the result...
Patients at increased risk for atrial fibrillation wearing iRhythm’s Zio patch — a continuous ECG monitoring wearable — were more likely to have their atrial fibrillation diagnosed early and receive subsequent preventive care, according to one-year results from a late-breaking study presented at the American College of Cardiology’s annual meeting.
The mHealth Screening to Prevent Strokes (...
Connected wearable patch makers will ship 35.1 million units annually by 2022, with 80 percent of these being used in clinical applications, according to a recent report from market intelligence firm Tractica.
The report also forecasts a total $7.9 billion in revenue for the patch market by the same year, all of which suggests a substantial escalation from the 966,000 units the analysts wrote...
iRhythm Technologies, maker of the ZIO patch peel-and-stick heart monitor, announced on its second quarter earnings call that it increased its revenue 52 percent year over year (for a total revenue of $23.9 million) and achieved its first cash flow break-even quarter.
CEO Kevin King also shared a rough timetable for the company's forthcoming Zio AT product, which received FDA clearance in June....
A team of researchers from Stanford University, working with cardiac monitoring company iRhythm, have created an AI algorithm that, in a small proof-of-concept trial, outperformed board-certified cardiologists at identifying various types of arrhythmias from ECGs. The results have been published to arXiv, an online archive for scientific papers, but have not yet appeared in a peer-reviewed...
